Donadio-Andréi S, Chikh K, Heuclin C, Kuczewski E, Charrié A, Gauchez AS, et al. Variability among TSH measurements can be reduced by combining a glycoengineered calibrator to epitope-defined immunoassays. Eur Thyroid J 2017;6:3–11.PubMedWeb of ScienceCrossrefGoogle Scholar
Rix M, Laurberg P, Porzig C, Kristensen SR. Elevated thyroid-stimulating hormone level in a euthyroid neonate caused by macro thyrotropin-IgG complex. Acta Paediatr 2011 Feb 25. doi: 10.1111/j.1651-2227.2011.02212.x. Epub 2011 Mar 7.Web of ScienceGoogle Scholar
Hattori N, Ishihara T, Matsuoka N, Saito T, Shimatsu A. Anti-thyrotropin autoantibodies in patients with macro-thyrotropin and long-term changes in macro-thyrotropin and serum thyrotropin levels. Thyroid 2017;27:138–46.PubMedCrossrefWeb of ScienceGoogle Scholar
Ram S, Harris B, Fernando JJ, Gama R, Fahie-Wilson M. False-positive polyethylene glycol precipitation tests for macroprolactin due to increased serum globulins. Ann Clin Biochem 2008;45:256–9.Web of ScienceCrossrefPubMedGoogle Scholar
Ellis MJ, Livesey JH. Techniques for identifying heterophile antibody interference are assay specific: study of seven analytes on two automated immunoassay analyzers. Clin Chem 2005;51:639–41.CrossrefPubMedGoogle Scholar
Donadio S, Morelle W, Pascual A, Romi-Lebrun R, Michalski JC, Ronin C. Both core and terminal glycosylation alter epitope expression in thyrotropin and introduce discordances in hormone measurements. Clin Chem Lab Med 2005;43: 519–30.PubMedGoogle Scholar
About the article
Published Online: 2018-10-31
Published in Print: 2019-05-27
Author contributions: NH as a pediatrician has managed thyroid test abnormalities of the family studied here and has sent the samples to AC and KC. EPC has managed thyroid test. KC, AC, SDA, EK, ASG and CR have designed biochemical investigations. SDA has performed biochemical tests. KC has performed bioactivity tests. VR has performed gel chromatography. KC, AC, ASG, CR and SDA analyzed and interpreted the data. ASG, CR, KC and SDA wrote the first drafts of the manuscript, and all authors read and commented the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This work was supported by public funds (salaries of NH, VV, EPC, EK, AC, ASG and KC and reagents by hospitals) and by private funds (salaries of SDA and CR).
Employment or leadership: The work presented in this publication is not patented. CR is a founder and shareholder of Siamed’Xpress, and SDA is a senior manager of the company. The biotech company holds two patents, one on methods for producing sialylated therapeutic proteins (PCT/EP2014/001904) of which CR is inventor and one on the screening of glycoform-specific antibodies (PCT/EP2005/001160) of which SDA and CR are coinventors.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.